Viewing Study NCT00441168

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:38 PM
Ignite Modification Date: 2025-12-27 @ 7:13 AM
Study NCT ID: NCT00441168
Status: TERMINATED
Last Update Posted: 2014-03-21
First Post: 2007-02-27
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
Sponsor: Janssen-Cilag International NV
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Multiple Myeloma View
None bortezomib View
None Cancer View
None Hematology View
None bone marrow View
None immunoglobulin View
None relapse View
None refractory View
None plasma cell View
None Velcade View
None adriamycin View
None dexamethasone View
None vincristine View